BioSpace News Archive

The U.S. Food and Drug Administration approved Pfizer’s once-per-day oral medication Vizimpro, a first-line treatment for patients with a rare form of lung cancer, the company announced late Thursday.

Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).

An estimated 15 million people in the United States have allergies to more than 170 different foods, according to the non-profit Food Allergy Research and Education. New health data suggests the frequency of food allergies in children under 18 has risen 70 percent since 1997, CNBC reported.

Kalamazoo Valley Community College’s Groves Center has announced a full lineup of Going Pro Talent Fund offerings for 2019.

Join Ellis Martin for a conversation with Jerome Jabbour, CEO and Director of Matinas Biopharma

Advanced Bifurcation Systems today announced that the Company has been granted four additional patents, three in the U.S. and one in Europe.

Dance Biopharm Holdings Inc. is pleased to announce that Anne Whitaker has been appointed as a Director and Chief Executive Officer.

Sareum Holdings plc announces that it has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers.

GeoVax Labs, Inc. announced today that the U.S. Department of Defense (DoD) has awarded the Company a $2,442,307 cooperative agreement in supportof its novel Lassa Fever (LF) vaccine development program.

Advanced Bifurcation Systems today announced that the Company has submitted a proposal to the U.S. Federal Drug Administration (“FDA”) for a clinical study leading to an IDE for its bifurcation technology. Concurrently, the Company is defining a regulatory and clinical strategy for Europe to receive a CE mark.